Literature DB >> 29440279

Impairment of PPARα and the Fatty Acid Oxidation Pathway Aggravates Renal Fibrosis during Aging.

Ki Wung Chung1,2, Eun Kyeong Lee1,2,3, Mi Kyung Lee4, Goo Taeg Oh5, Byung Pal Yu6, Hae Young Chung7,2.   

Abstract

Defects in the renal fatty acid oxidation (FAO) pathway have been implicated in the development of renal fibrosis. Although, compared with young kidneys, aged kidneys show significantly increased fibrosis with impaired kidney function, the mechanisms underlying the effects of aging on renal fibrosis have not been investigated. In this study, we investigated peroxisome proliferator-activated receptor α (PPARα) and the FAO pathway as regulators of age-associated renal fibrosis. The expression of PPARα and the FAO pathway-associated proteins significantly decreased with the accumulation of lipids in the renal tubular epithelial region during aging in rats. In particular, decreased PPARα protein expression associated with increased expression of PPARα-targeting microRNAs. Among the microRNAs with increased expression during aging, miR-21 efficiently decreased PPARα expression and impaired FAO when ectopically expressed in renal epithelial cells. In cells pretreated with oleic acid to induce lipid stress, miR-21 treatment further enhanced lipid accumulation. Furthermore, treatment with miR-21 significantly exacerbated the TGF-β-induced fibroblast phenotype of epithelial cells. We verified the physiologic importance of our findings in a calorie restriction model. Calorie restriction rescued the impaired FAO pathway during aging and slowed fibrosis development. Finally, compared with kidneys of aged littermate controls, kidneys of aged PPARα-/- mice showed exaggerated lipid accumulation, with decreased activity of the FAO pathway and a severe fibrosis phenotype. Our results suggest that impaired renal PPARα signaling during aging aggravates renal fibrosis development, and targeting PPARα is useful for preventing age-associated CKD.
Copyright © 2018 by the American Society of Nephrology.

Entities:  

Keywords:  Aging; Fatty acid oxidation; PPARα; fibrosis; miR21

Mesh:

Substances:

Year:  2018        PMID: 29440279      PMCID: PMC5875952          DOI: 10.1681/ASN.2017070802

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  53 in total

1.  Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males.

Authors:  D F DAVIES; N W SHOCK
Journal:  J Clin Invest       Date:  1950-05       Impact factor: 14.808

Review 2.  MicroRNAs in stress signaling and human disease.

Authors:  Joshua T Mendell; Eric N Olson
Journal:  Cell       Date:  2012-03-16       Impact factor: 41.582

Review 3.  Regulation of SIRT1 in aging: Roles in mitochondrial function and biogenesis.

Authors:  Yujia Yuan; Vinicius Fernandes Cruzat; Philip Newsholme; Jingqiu Cheng; Younan Chen; Yanrong Lu
Journal:  Mech Ageing Dev       Date:  2016-03-07       Impact factor: 5.432

4.  Aging-induced decrease in the PPAR-alpha level in hearts is improved by exercise training.

Authors:  Motoyuki Iemitsu; Takashi Miyauchi; Seiji Maeda; Takumi Tanabe; Masakatsu Takanashi; Yoko Irukayama-Tomobe; Satoshi Sakai; Hajime Ohmori; Mitsuo Matsuda; Iwao Yamaguchi
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-11       Impact factor: 4.733

Review 5.  MicroRNAs in kidney physiology and disease.

Authors:  Piera Trionfini; Ariela Benigni; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2014-11-11       Impact factor: 28.314

6.  Obesity and change in estimated GFR among older adults.

Authors:  Ian H de Boer; Ronit Katz; Linda F Fried; Joachim H Ix; Jose Luchsinger; Mark J Sarnak; Michael G Shlipak; David S Siscovick; Bryan Kestenbaum
Journal:  Am J Kidney Dis       Date:  2009-09-25       Impact factor: 8.860

7.  Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging.

Authors:  M E Poynter; R A Daynes
Journal:  J Biol Chem       Date:  1998-12-04       Impact factor: 5.157

Review 8.  Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis.

Authors:  Philippe Lefebvre; Giulia Chinetti; Jean-Charles Fruchart; Bart Staels
Journal:  J Clin Invest       Date:  2006-03       Impact factor: 14.808

9.  Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators.

Authors:  S S Lee; T Pineau; J Drago; E J Lee; J W Owens; D L Kroetz; P M Fernandez-Salguero; H Westphal; F J Gonzalez
Journal:  Mol Cell Biol       Date:  1995-06       Impact factor: 4.272

10.  Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy.

Authors:  Michal Herman-Edelstein; Pnina Scherzer; Ana Tobar; Moshe Levi; Uzi Gafter
Journal:  J Lipid Res       Date:  2013-12-26       Impact factor: 5.922

View more
  58 in total

1.  Genetic deficiency or pharmacological inhibition of miR-33 protects from kidney fibrosis.

Authors:  Nathan L Price; Verónica Miguel; Wen Ding; Abhishek K Singh; Shipra Malik; Noemi Rotllan; Anna Moshnikova; Jakub Toczek; Caroline Zeiss; Mehran M Sadeghi; Noemi Arias; Ángel Baldán; Oleg A Andreev; Diego Rodríguez-Puyol; Raman Bahal; Yana K Reshetnyak; Yajaira Suárez; Carlos Fernández-Hernando; Santiago Lamas
Journal:  JCI Insight       Date:  2019-11-14

2.  Proximal Tubule Translational Profiling during Kidney Fibrosis Reveals Proinflammatory and Long Noncoding RNA Expression Patterns with Sexual Dimorphism.

Authors:  Haojia Wu; Chun-Fu Lai; Monica Chang-Panesso; Benjamin D Humphreys
Journal:  J Am Soc Nephrol       Date:  2019-09-19       Impact factor: 10.121

Review 3.  The role of PPARα in autosomal dominant polycystic kidney disease.

Authors:  Ronak Lakhia
Journal:  Curr Opin Nephrol Hypertens       Date:  2020-07       Impact factor: 2.894

4.  Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Lauren Pickel; Ioan-Andrei Iliuta; James Scholey; York Pei; Hoon-Ki Sung
Journal:  Adv Nutr       Date:  2021-11-10       Impact factor: 8.701

Review 5.  Targeting fatty acid metabolism for fibrotic disorders.

Authors:  Seonghwan Hwang; Ki Wung Chung
Journal:  Arch Pharm Res       Date:  2021-10-18       Impact factor: 4.946

6.  Astaxanthin attenuates hepatic steatosis in high-fat diet-fed rats by suppressing microRNA-21 via transactivation of nuclear factor erythroid 2-related factor 2.

Authors:  Abdullah S Shatoor; Suliman Al Humayed; Hussain M Almohiy
Journal:  J Physiol Biochem       Date:  2021-10-15       Impact factor: 4.158

Review 7.  The role of metabolic reprogramming in tubular epithelial cells during the progression of acute kidney injury.

Authors:  Zhenzhen Li; Shan Lu; Xiaobing Li
Journal:  Cell Mol Life Sci       Date:  2021-06-29       Impact factor: 9.261

Review 8.  Druggability of lipid metabolism modulation against renal fibrosis.

Authors:  Yuan-Yuan Chen; Xiao-Guang Chen; Sen Zhang
Journal:  Acta Pharmacol Sin       Date:  2021-05-14       Impact factor: 6.150

9.  Pre-emptive pharmacological inhibition of fatty acid-binding protein 4 attenuates kidney fibrosis by reprogramming tubular lipid metabolism.

Authors:  Yuting Chen; Yue Dai; Kaixin Song; Yi Huang; Le Zhang; Cuntai Zhang; Qi Yan; Hongyu Gao
Journal:  Cell Death Dis       Date:  2021-06-03       Impact factor: 8.469

Review 10.  Therapeutic and diagnostic targeting of fibrosis in metabolic, proliferative and viral disorders.

Authors:  Alexandros Marios Sofias; Federica De Lorenzi; Quim Peña; Armin Azadkhah Shalmani; Mihael Vucur; Jiong-Wei Wang; Fabian Kiessling; Yang Shi; Lorena Consolino; Gert Storm; Twan Lammers
Journal:  Adv Drug Deliv Rev       Date:  2021-06-15       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.